Anaesthesia
Anaesthesia
Anaesthesia Revision - 1 1
Anaesthesia Revision - 2 7
Anaesthesia Revision - 3 18
Anaesthesia Revision - 4 23
Anaesthesia Revision - 5 27
Anaesthesia Revision - 6 34
om
l.c
ai
gm
@
er
ck
a
cr
ut
gn
in
az
m
ea
th
|
w
ro
ar
M
©
©
M
ar
ro
w
|
th
ea
m
az
in
gn
ut
cr
ack
er
@
gm
ai
l.c
om
Anaesthesia Revision - 1 1
om
• Discontinued :
l.c
- OHA & Insulin : On surgery day (Risk of hypoglycemia).
ai
Diabetes mellitus
- SGLT-2 inhibitors : 24 hrs prior (Risk of eugylcemic ketoacidosis).
gm
• Intra-op Start regular short acting insulin.
@
er
• Continue antiepileptics till day of Sx.
ck
a
Continue antipsychotics.
|
w
Exceptions :
ro
• Lithium/Mg :2+
- Stop 24-48 hours prior if used along with long acting muscle relaxants
(Prolong their action).
- Can be continued with short acting muscle relaxants like Mivacurium & Atracurium.
Nerve compression
(Permanent damage).
• Anticoagulants discontinued prior to RA :
- Aspirin : Continued/stopped 3 days prior if ↑risk of bleeding.
Anticoagulants - Clopidogrel
5-7 days prior.
- Warfarin
• Bridging with LMWH to prevent re-infarction :
- LMWH Prophylactic dose : Stop 12 hours prior.
Therapeutic dose : Stop 24 hours prior.
- Regular heparin : Stop 6 hours prior.
om
• Topical anesthesia : Continue anticoagulants.
l.c
ai
gm
Personal History :
@
er
ck
Condition Features
a
cr
• ↑ Risk of bronchospasm :
in
- Clinical features :
az
Smoking - Rx : Bronchodilators.
|
w
Family History :
Malignant hyperthermia :
• Etiology : All inhalational agents & Succinyl choline.
• Risk factor : Strong family h/o muscular dystrophies.
• Pathophysiology : R yanodine receptor mutation (Sarcoplasmic reticulum)
om
Allergy History :
l.c
ai
Causes anaphylactic shock (Histamine : vasodilator & bronchoconstrictor).
gm
@
Etiology : er
ck
a
Clinical presentation :
in
az
• Edema (Lips/face/airway).
|
w
ro
Mx :
ar
M
- IV dose : 1 mL of 1 : 10000.
- IM / SC dose : 0.5 mL of 1 : 1000.
• Hydrocortisone.
• Adequate fluids.
Risk Factors :
• H/o difficult intubation.
• Airway anomalies.
om
l.c
ai
gm
@
er
ack
Thyromental distance
cr
ut
Sternomental distance
gn
in
az
m
ea
th
|
Mallampati scoring :
w
ro
Mallampati scoring
ar
M
ASA Grading :
Based on functional capacity.
om
l.c
Investigations :
ai
gm
Minimum laboratory parameters for various scenarios :
@
Parameters er Value
ck
a
Minimum acceptable platelet count for invasive procedure (Central line/liver biopsy) 50,000
ea
ECHO ECG
• Dyspnoea of unknown origin. • K/c/o IHD.
Mandatory • Heart failure patients with worsening • Significant arrythmia PAD, CVD.
dyspnoea. • Significant structural heart disease.
May be • Past h/o LV dysfunction not • Major Sx in asymptomatic patients
done evaluated since l yr. without h/o coronary heart disease
Not • Asymptomatic patients.
• As routine investigation.
performed • Low risk surgical procedures.
----- Active space ----- Elective surgery : Thoroughly evaluate for the following & then do Sx
• ACS. • Significant arrhythmias.
• Decompensated HF. • Valvular heart disease.
Risk assessment for developing MI :
Parameter Score Score Risk of cardiac complication
High risk surgery 1 0 0.4 %
H/o ischemic heart disease 1 1 1.0 %
H/o congestive cardiac failure 1 2 2.4 %
H/o cerebrovascular accident 1 ≥3 5.4 %
H/o diabetes mellitus requiring insulin 1
Serum creatinine >2.0 1
om
Stress testing : Perform if functional capacity <4 METS.
l.c
Criteria for performing Sx after coronary stenting :
ai
gm
• Bare metal stent : Wait for 1 month.
@
• Drug eluting stent (M/c) : Wait for 6 [Link]
er
a
CNS Monitoring
Depth of anesthesia (Absence of awareness) is monitored.
Bispectral Index :
• Analyzes EEG waveforms.
• 40 to 60 : Recommended range for GA. Bispectral Index
om
CVS Monitoring :
l.c
ai
gm
HR BP ECG Central venous Pulmonary Echocardiography
@
• Arrhythmias : Lead II er
pressure
ck
Capillary Wedge
• Ischemia
a
Pressure
cr
ut
(PCWP)
gn
in
• Oscillatory. circulation
ar
M
(Automatic)
©
Triple lumen
Image • Size : 7 Fr (20 cms)
• Inserted in IJV.
RS Monitoring :
om
Pulse Oximeter :
l.c
ai
• Measures oxygenation. • Limitations :
gm
• Principle : Beer Lambert’s law.
@
- CO poisoning : SpO2 falsely↑
• Emits : er
- Meth Hb, dyes : SpO2↓
ack
Absorbed by
cr
Absorbed by
gn
Capnography :
m
ea
Expired CO2
Time Time
Bronchospasm/Partially obstructed ET tube Cardiogenic oscillations
• Increased upstroke of phase III. Physiological in children (D/t thin chest wall).
• Shark fin pattern.
Expired CO2
Expired CO2
Curare cleft
om
l.c
ai
Time Time
gm
Recovering from the effect of muscle Hypoventilation
@
relaxant Seen in opium poisoning (CNS depressant)
If curare cleft seen : er
ck
a
10
ea
th
5
|
w
0
ro
Time
ar
Expired CO2
Elevated
Time Time
Leaky sampling line baseline Rebreathing of CO2
Dual plateau sign. Exhausted soda lime/inadequate fresh gas flow
A B
Expired CO2
Expired CO2
β
6
4
2
0
Time
Time
Incompetent inspiratory valve Single lung transplant
Slaying of phase IV. 2 peaks in phase III
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024
10 Anaesthesia
Expired CO2
50
37
CO2 (mmHg)
0
Time Time
Sudden zeroing of EtCO2 Intubation into esophagus
• Accidental extubation/circuit disconnection (M/c)
• Venous air embolism
Neuromuscular Monitoring :
Use : To check adequate muscle relaxation after Sx.
om
Train Of Four (TOF) stimulation :
l.c
• Muscle contraction noted on 4 equal
ai
gm
supramaximal stimulus. Ulnar nerve monitoring (M/c)
@
• TOF ratio (4th stimulus/1st stimulus) : > 0.9 ck
er (Adductor policis muscle)
a
Normal NDMR
©
Temperature Monitoring :
Hypothermia : Hyperthermia :
• D/t depressed hypothalamus, Malignant hyperthermia, sepsis.
chilled OT & IV fluids.
• Under anesthesia : ↓Shivering threshold.
Monitoring :
Site Areas for measurement
Neuro Sx Tympanic membrane, nasopharynx
Core body temperature Cardio Sx Pulmonary artery (Most accurate)
Other Sx Lower esophagus (M/c done)
Intermediate Rectum (Wards, casualty)
Not reliable Skin, Axilla
Note : Bladder temperature Not performed since values affected by urine flow.
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024
Anesthesia Revision - 2 11
Pre-oxygenation :
om
falling back) Jaw thrust
l.c
Jaw thrust
ai
gm
Recent updates : Head tilt & chin lift
@
er O2 ↑Apnea time by
ck
a
cr
13 minutes
gn
Guedel’s airway :
w
ro
Neck extension
Oral axis is Scissor’s method
aligned with the (To extend the lower jaw)
other 2 axes.
om
10-15 cm pillow/head
l.c
ring behind the occiput
ai
gm
Helps align pharyngeal &
@
er
laryngeal axes.
ck
Sniffing of morning air/Drinking of pint beer position
a
cr
Laryngoscopes :
ea
th
Image
om
Endotracheal Tube (ETT) :
l.c
ai
Types :
gm
Murphy’s eye : A lternate
@
ventilation er
ck
a
cuff
gn
in
(Prevents aspiration)
th
|
Microcuffed ETT
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024
14 Anaesthesia
RAE ETT :
• South facing : Cleft lip surgeries. • North facing : Lower lip Sx
om
l.c
ai
gm
@
er
ack
cr
ut
Accessory Gadgets :
gn
Advanced Gadgets :
Flexible fiber optic bronchoscope :
• Gold standard for ETT position.
• Used in restricted mouth opening & lung Sx.
om
01:17:40
l.c
ai
LARYNGEAL MASK AIRWAY (LMA) :
gm
First Generation :
@
Classical LMA : (Made of Latex) er LMA Unique :
ck
• Made of PVC.
a
Laparoscopy, Pregnancy.
ea
th
|
Superior part :
w
Base of tongue
ro
Intubating LMA
ar
M
Lateral walls :
©
On pyriform fossa
Tip :
Above esophageal sphincter
Second generation :
D/t drain tube (For removal of aspirate).
Proseal LMA : LMA Supreme : IGEL :
Drain tube
Drain
tube Drain tube
om
Cricoid pressure removed after :
l.c
ai
Intubation & cuff inflation.
gm
Selick’s Maneuver
Muscle relaxant Succinylcholine (Short acting) Rocuronium
@
Induction AOC Thiopentone sodium er
Propofol
ack
cr
Awake intubation :
in
az
• Transtracheal injection :
Blocks recurrent laryngeal nerve
Plan A :
Facemask ventilation Succeed Tracheal intubation
Laryngoscopy
& tracheal intubation
Failed intubation
Plan B :
Maintaining oxygenation : Supraglottic Succeed Stop and think :
SAD insertion Airway Device Options (Consider risks & benefits)
(SAD) 1. Wake the patient up.
2. Intubate trachea via the SAD.
3. Proceed without intubating the trachea.
4. Tracheostomy/cricothyroidotomy.
Failed SAD ventilation
om
l.c
Plan C :
ai
Facemask ventilation Final attempt at face Succeed
gm
Wake the patient up
mask ventilation
@
Can’t Intubate, Can’t er
ck
a
Oxygenate (CICO)
cr
ut
gn
Plan D :
in
of neck access
m
ea
th
|
w
ro
ar
M
©
om
• Act on GABA receptors : ↑Chloride conductance Membrane hyperpolarization.
l.c
ai
gm
BARBITURATES
@
Good antiepileptic action (Except Methohexital).
ck
er
a
cr
Thiopentone Sodium :
ut
gn
General properties : Yellow powder of pH 10.5 (Most alkaline) with garlic/onion smell.
in
Metabolism :
ea
th
• Highly lipophilic.
|
w
Use :
• AOC :
- Neurosurgeries (Max. ↓ICP). - Hyperthyroidism
• Truth serum.
Complication :
• Accidental intraarterial administration : Pain, pallor, edema, gangrene.
Mx : Retain cannula (To prevent vasospasm).
- Saline/heparin flush.
- Stellate ganglion block (Lower cervical sympathetic ganglion).
Methohexital :
Disadvantage : Proconvulsant (Avoided in neurosurgeries).
Indication : Electroconvulsive therapy.
Dose : 1-1.5 mg/kg (More potent than thiopentone).
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024
Anaesthesia Revision - 3 19
• Dissociative anaesthesia,
Depressant (In vivo).
Properties Antiemetic & antipruritic Most cardiostable
• NMDA receptor antagonist
(↑Catecholamine release).
• IV : 1-2 mg/kg.
Dose 1-2.5 mg/kg 0.2-0.3 mg/kg
om
• IM : 4-6 mg/kg.
l.c
Onset 15 sec - -
ai
gm
Intrathecally used with
Duration 8-10 min (Without hangover) -
@
LA to ↑duration
er
ck
• Day care/ambulatory Sx &
a
• Asthma/COPD : Good
gn
• Tetralogy of Fallot.
choice (↓ reflexes). • DC
m
• Paediatric Sx.
w
• ↑Oral secretions
M
(Rx : Atropine/
©
Characteristics :
• Maintain depth of anaesthesia.
• Induce sleep (Paediatric).
• Depressants.
• Enter & exit the circulation via lungs.
om
1
• Potency ∝ .
l.c
MAC values
ai
gm
Least MAC Highest MAC
@
er
ack
Most potent Methoxyflurane Halothane Isoflurane Sevoflurane Desflurane N2O Least potent
cr
ut
gn
Machine to Alveoli :
m
ea
a. Concentration effect :
th
Note :
Diffusion hypoxia/Fink effect (End of Sx) :
• Rapid diffusion of N20 from pulmonary circulation Dilution of O2.
• Mx : 02 supplementation.
om
• Sweet scent Sx (Sweet
Pulmonary Avoid in Avoid in
l.c
(2nd choice in children) scene).
asthmatics. asthmatics.
ai
system : Note : Contains thymol • Daycare Sx.
gm
↓RR (Preservative) • Lung injury.
@
• ↓ Pulmonary vascular resistance. er
ck
• Mild hypoxic pulmonary vasoconstriction.
a
cr
ut
phenomenon.
ro
ar
• C/I in neurosurgery
blood flow Used in neurosurgery.
(CBF)
Note : Enflurane causes seizures.
↑ ICP.
• Max ↓LBF.
Minimally
GIT, liver and • Metabolite causes - -
metabolised.
biliary tract : Halothane hepatitis in
↓Liver blood old age, female,
flow (LBF) 40 yrs, obese, multiple Hepatic insufficiency : Either of 3 used
exposure.
om
Note : Trilene Only analgesic.
l.c
ai
gm
Effects of N2O :
@
• Proven teratogen. er
ck
• Disrupts Vit B12 metabolism :
a
cr
ut
- Megaloblastic anemia.
gn
• C/I in :
m
ea
- Pneumothorax/pneumomediastinum.
th
|
om
Onset of action 30 seconds
l.c
AOC Difficult intubation/rapid sequence intubation
ai
gm
• Non competitive blockade : Ach receptor.
Mechanism of action
@
• Metabolised by pseudocholinesterase. (PSE : Produced by liver).
er
ck
• Bradyarrhythmia (Rx with Atropine/Glycopyrrolate).
a
cr
• Muscle fasciculations :
ut
• Anaphylaxis
m
ea
• Preexisting hyperkalemia.
|
• Burns.
w
C/I
ro
• Sepsis.
M
©
• Hemiplegia/paraplegia.
om
Non Depolarizing Muscle Relaxants (NDMR)
l.c
ai
gm
Types :
@
: Steroidal compounds. er : Benzylisoquinolone compounds.
ack
cr
• Avoid in day-care Sx
Pancuronium Excretion : Kidney AOC : Shock
in
Vecuronium Excretion : Bile AOC : Cardiac & neuro Sx Avoid in hepatic insufficiency
ea
th
Metabolism :
M
om
l.c
Preoperative Preparation :
ai
gm
To ↓anxiety :
@
• Benzodiazepine syrup (Midazolam). er
ck
• Ketamine IM : 4-6 mg/kg. Children > 6 months age
a
cr
ut
Fasting guidelines :
m
om
• ↓ Risk of hospital infection.
l.c
ai
• All regional anaesthesia procedures can be done in day care setting.
gm
@
Prerequisites : ck
er
Patient factors :
a
I & II.
cr
Procedure factors :
|
w
ro
• C/I
©
Complication :
• M/c : Drowsiness, nausea & vomiting.
• M/c cause for readmission : Hemorrhage.
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024
Anaesthesia Revision - 5 27
Regional anaesthesia :
Indications :
om
Below umbilical surgeries.
l.c
ai
gm
Absolute C/I :
@
• ↑ICP. • Severe hypovolemia.
er
ck
• Bleeding tendencies. • Severe mitral & aortic stenosis.
a
cr
• Patient refusal.
in
az
m
Site :
ea
th
• Adults : L3 - L4.
|
• Children : L4 - L5.
w
ro
ar
Procedure :
M
©
om
• Pregnancy : ↑Intraabdominal pressure ↑Subarachnoid &
l.c
ai
↑Blockade d/t epidural venous pressure.
gm
Progesterone (Nerves become sensitive).
@
Procedure factors : er
ck
Position : Related to baricity.
a
cr
ut
Drug factors :
|
w
Technique :
Loss of resistance (LOR) technique.
Tuhoy needle
LOR syringe
Epidural catheters
om
• ↑Duration of anaesthesia.
l.c
ai
• Used in post-op analgesia.
gm
@
• No risk of PDPH (As long as dura is not accidentally punctured).
• Stable hemodynamics. er
ck
a
cr
ut
Disadvantages :
gn
• Inadequate blockade.
m
ea
• Accidental catheter migration Subarachnoid Space : Total spinal anaesthesia (Mx : Intubation).
w
ro
Axillary approach
om
Classification :
l.c
ai
Amides Esters
gm
• Stable solution • Unstable solution
@
Physical property
• er
↓Incidence of allergic reaction • ↑Incidence of allergic reaction
ack
In liver By plasma esterase
cr
Metabolism
ut
• Lignocaine
in
Examples • Procaine
az
• Bupivacaine
m
ea
MoA :
th
Sequence of Blockade :
©
Toxicity :
Lignocaine : Seizures mainly.
Mx : Midazolam.
Bupivacaine : Ventricular arrhythmias mainly.
Rx : 20% Intralipid (1.5 ml/kg bolus, 0.25 ml/kg/hr infusion).
Cocaine : ↑BP & causes angina.
Rx : Nitroglycerine.
Prilocaine : Methemoglobinemia d/t ortho-toluidine..
om
l.c
Applications :
ai
gm
EMLA Cream : 2.5% lignocaine + 2.5% prilocaine (IV Cannulation).
@
er
ck
Bier’s block :
a
cr
• Drugs :
in
az
- C/I : Bupivacaine.
ea
th
Labour Analgesia :
©
ZONES
• High pressure (Main : Gas cylinders).
• Intermediate pressure.
• Low pressure.
om
• Molybdenum steel alloy. Non-liquifiable gas : Bourdon’s pressure gauge.
l.c
ai
• Aluminum (For use in Liquifiable gas : Manually weighing the cylinder.
gm
MRI rooms).
@
er
ck
Safety features :
a
Air 1, 5
|
w
O2 2, 5
ro
ar
N2O 3, 5
M
©
CO2 <7.5% 2, 6
PISS
CO2 >7.5% 1, 6
Cyclopropane 3, 6
Entonox 7
Pipeline
pressure
indicator
BREATHING CIRCUITS
Mapleson’s/Semi Closed Circuits :
Advantage : Easy transportation. APL Valve
Disadvantage : Heavy FGF. Co-axial circuit
om
Patient end
l.c
Reservoir bag
ai
gm
Types : Bain’s circuit
@
er
ck
Adjustable pressure
a
cr
ut
gn
Corrugate tube
in
Reservoir
az
m
bag Patient
ea
th
om
l.c
Put pt. in left Normal No normal
ai
gm
lateral position & breathing breathing
and but
@
er
pulse felt pulse felt
Using ambu bag
ack
cr
ut
gn
a rate of 100-120/min.
ar
high-quality
M
by quantitative waveform
capnography.
Rhythm is Rhythm is
shockable not shockable
Advanced Cardiac Life Support (ACLS Algorithm) 00:06:43 ----- Active space -----
1
� Start CPR
� Give Oxygen
� Attach defibrillator
Rhythm shockable?
Yes No
2 9
VF/pVT Asystole/PEA
om
10
3 Defibrillate � Intravenous/intraosseous access
l.c
� Epinephrine ASAP & 1 mg every
ai
4
gm
� Resume CPR x 2min 3-5 min.
� (Even if defibrillation worked) � CPR x 2min
@
er
� Intravenous/interosseous
intraosseous access
access ck � ET intubation
a
cr
Rosc
ROSC Rosc
ROSC
arrest care arrest care
gn
No No
in
az
Management VF/PVT
ea
Yes No
th
11
|
5 Defibrillate
w
� CPR 2 min
ro
� CPR X 2min
M
7 Defibrillate
No
Drug therapy :
• Epinephrine IV/10 dose : 1 mg every 3-5 minutes (1 : 1000).
• Amiodarone IV/10 doses :
- First dose : 300 mg bolus.
- Second dose : 150 mg or,
• Lidocaine IV/IO :
- First dose : 1-1.5 mg.
Reversible cause :
om
• Hypovolemia.
l.c
• Hypoxia.
ai
gm
• Hydrogen ion (Acidosis). 5 Hs
@
• Hypo/hyperkalemia. er
ck
• Hypothermia.
a
cr
ut
gn
• Tension pneumothorax.
in
az
• Cardiac Tamponade.
m
ea
• Toxins. 5 Ts
th
• Thrombosis (Pulmonary).
|
w
• Thrombosis (Coronary).
ro
ar
M
om
• Consider adenosine if
l.c
narrow QRS complex. • Antiarrhythmic infusion. • Vagal maneuvers.
ai
• Consider adenosine only if • Adenosine.
gm
regular and monomorphic. • β blockers/ Ca2+ channel blockers.
@
er
ck
Antiarrhythmic infusion :
a
cr
• Procainamide : • Sotalol :
ut
gn
Bradycardia
Note :
Hemodynamically stable Hemodynamically unstable • Bradycardia :
HR <60 bpm.
Monitor & observe. • Atropine IV 1 mg bolus • Bradyarrhythmia :
• Repeat every 3-5 mins HR <50 bpm.
• Maximum dose : 3 mg
not effective
Transcutaneous pacing/Dopamine infusion/Epinephrine infusion.
Anaesthesia Revision • v4.0 • Marrow 8.0 • 2024